(CercleFinance.com) – Liberum believes Bayer’s recent results have shown strong performance across all divisions and the company has established an encouraging outlook for 2022.
“Notably, significant pipeline progress has improved the mid-term outlook for the pharmaceutical division. The data for Nubeqa in hormone-sensitive prostate cancer fully supports Bayer’s revised target of maximum sales of over €3 billion,” the analysts said.
‘We are eagerly awaiting the first phase II results of Bayer’s new anticoagulant, asundexian, in early April, which could be a long-term improvement to Xarelto’ adds Liberum.
The analyst confirms his advice to buy the stock and raises his target price to 82 E (instead of 74 E) after the announcement of the results.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
